SynthesisPloS one2012

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.

Si-wei Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.